Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse Journal Article
| Authors: | Hu, R.; Wei, W.; Mian, A.; Gonter-Aubin, K.; Kabel, C.; Mato, A.; Stephens, D. M.; Hanlon, A.; Khajavian, S.; Shadman, M.; Brander, D.; Madanat, Y.; Park, J. H.; Tallman, M.; Pinilla-Ibarz, J.; Hill, B. T. |
| Article Title: | Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse |
| Abstract: | Introduction: Frontline treatment of hairy cell leukemia (HCL) with a single course of the purine nucleoside analog (PNA) produces a high rate of complete remission (CR) with prolonged durations. At the time of relapse, although treatment guidelines recommend re-treatment with a PNA alone or in combination with rituximab (R), practice patterns vary and data supporting each approach are limited. Methods: We conducted a multisite outcomes analysis of patients treated for HCL between 1995 and 2018 at six US medical centers. All patients were treated with frontline PNA and subsequently required treatment with a PNA alone (PNA) or with R (+R). Results: Of the 88 patients analyzed, 56 (63.6%) received second-line PNA and 22 (36.4%) received a PNA + R. Baseline characteristics of both groups were similar. There was no difference in median PFS [67 months (95% CI 43.8 non-reached (NR)) vs. 65 months (95% CI 60-NR)] or 5-year OS [98% (95% CI 0.94–1) vs. 94% (95% CI 0.83–1), p =.104] in the PNA versus PNA + R cohorts, respectively. Conclusion: To our knowledge, this is the largest study evaluating the role of R in treatment of relapsed HCL and suggests that there is no advantage to the addition of R to PNA therapy at the time of first re-treatment. © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
| Keywords: | treatment outcome; rituximab; recurrence; recurrent disease; purines; purine derivative; nucleoside; hairy cell leukemia; purine; nucleosides; purine nucleoside analog; purine nucleosides; leukemia, hairy cell; purine nucleoside; humans; human |
| Journal Title: | European Journal of Haematology |
| Volume: | 108 |
| Issue: | 5 |
| ISSN: | 0902-4441 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2022-05-01 |
| Start Page: | 379 |
| End Page: | 382 |
| Language: | English |
| DOI: | 10.1111/ejh.13744 |
| PUBMED: | 35043475 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 June 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work